Xellera Therapeutics is a specialized Contract Development and Manufacturing Organization (CDMO) focused on Cell and Gene Therapy (CGT) and Advanced Therapy Products (ATP). The company delivers GMP-compliant manufacturing solutions across development stages, from process optimization and clinical supply to commercial-scale production. Through strong quality systems, regulatory expertise, and scalable technologies, Xellera Therapeutics supports the efficient advancement of innovative therapies to patients worldwide.
